Balance between large and small-caps, investment in cos with single-focus—should Sundaram Mid-cap fund make it to your portfolio?

ET Wealth collaborates with Value Research to analyze top mutual funds. We examine the key fundamentals of the fund, its portfolio, and performance to help you make an informed investment decision.

BASIC FACTS

DATE OF LAUNCH
30 JULY 2002
CATEGORY
EQUITY

TYPE
MID CAP
AUM*
Rs.12,619 crore
BENCHMARK
NIFTY MIDCAP 150
TOTAL RETURN INDEX

WHAT IT COSTS
NAV**
GROWTH OPTION
Rs.1221.11
IDCW
Rs.60.63
MINIMUM INVESTMENT
Rs.100

MINIMUM SIP AMOUNT
Rs.100

EXPENSE RATIO# (%)
1.72
EXIT LOAD
For units in excess of 25% of the investment, 1% will be charged for redemption within 365 days

*AS ON 31 DEC 2024
**AS ON 27 JAN 2025
#AS ON 31 DEC 2024

FUND MANAGER
BHARATH S/RATISH VARIER
3 YEARS, 10 MONTHS

Recent portfolio changes
New entrants
Blue Star (Nov), Mankind Pharma (Dec)
Complete exits
CG Power & Industrial Solutions, Laurus Labs,Sanofi Consumer Healthcare India (Nov)

Should You Buy?
This fund currently runs a sizeable presence in both large- and smallcaps, apart from its mid-cap tilt. It strives for a balance between structural and cyclical picks. The preference is for businesses that adopt a single-focus approach. The fund portfolio is heavily diversified, with the fund managers preferring modest exposure even in top bets to keep risks at bay. The fund struggled with chronic underperformance between 2017 and 2021. It has since improved its return profile while also elevating its risk metrics. A sustained improvement in performance could make this fund a worthy bet in this space.